TrialBritish journal of cancer2006

Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.

G Frasci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.